Tweet
Last Updated: July 31, 2023 at 2:50 p.m. ET
First Published: July 31, 2023 at 7:23 a.m. ET
By Ciara Linnane
Quest Diagnostics Inc. said Monday the first blood-based biomarker test to assess the risk of developing Alzheimer’s disease is now available for consumer purchase.
The test helps assess the risk of getting the disease based on the brain protein beta amyloid, which is known to accumulate and form plaques in the brain that are linked to the progression of Alzheimer’s disease.
“AD-Detect is a screening test that uses plasma, the liquid component of blood, from a single blood draw to evaluate levels of amyloid beta proteins to help detect early signs associated with the risk of developing Alzheimer’s disease,” Quest DGX, -0.45% said in a statement. ...
First Published: July 31, 2023 at 7:23 a.m. ET
By Ciara Linnane
Quest Diagnostics Inc. said Monday the first blood-based biomarker test to assess the risk of developing Alzheimer’s disease is now available for consumer purchase.
The test helps assess the risk of getting the disease based on the brain protein beta amyloid, which is known to accumulate and form plaques in the brain that are linked to the progression of Alzheimer’s disease.
“AD-Detect is a screening test that uses plasma, the liquid component of blood, from a single blood draw to evaluate levels of amyloid beta proteins to help detect early signs associated with the risk of developing Alzheimer’s disease,” Quest DGX, -0.45% said in a statement. ...